Skip to main content

Day: February 18, 2025

Icelandic Salmon – Ending a challenging year with a stable biological situation

Bíldudalur, 18 February 2025 Icelandic Salmon is the parent company of Arnarlax and its subsidiaries, which are involved in salmon farming and processing in Iceland. The companies are collectively referred to as “Icelandic Salmon” or the “Group”. With determined efforts in the fourth quarter of 2024, Icelandic Salmon stabilized the biological conditions in the sea after having experienced significant challenges in the winter-spring 2023‑24, resulting in higher harvest volumes and weights, and good sea lice control. To further strengthen the Group’s financial position, the group has agreed on an extension to its sustainability-linked financing agreement with DNB and Danske Bank. This agreement provides additional funding of EUR 65 million, increasing the total loan facility to EUR 160 million. In the fourth quarter...

Continue reading

SalMar – Satisfactory results and good biological development towards the end of the quarter

The fourth quarter of 2024 marks the end of a challenging year for SalMar. However, biological conditions and results improved significantly towards the end of the year, providing brighter prospects for 2025. Operational EBIT for Norway was NOK 1,485 million in the fourth quarter of 2024. The harvest volume was 67,300 tonnes, and operational EBIT per kg was NOK 22.1. Operational EBIT for the group was NOK 1,489 million in the fourth quarter of 2024. The harvest volume was 73,800 tonnes, and operational EBIT per kg was NOK 20.2. The farming segments in Norway had a good development throughout the quarter and delivered strong results. Sales and industry contributed positively with their efficient and flexible operational setup, delivering a good result. For SalMar Aker Ocean, the production cycles for both Arctic Offshore Farming and Ocean...

Continue reading

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS, Feb. 18, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by...

Continue reading

Trust Stamp Partners with Digital Platformer to Strengthen Security in Digital Identity and Financial Services

Trust Stamp and Digital Platformer unite to establish a strategic partnership, delivering an integrated solution that combines Trust Stamp’s advanced identity verification capabilities with Digital Platformer’s cutting-edge decentralized security solutions  This joint initiative aims to enhance financial security, identity authentication, and regulatory compliance across multiple industries, ensuring a seamless and privacy-first user experience Tokyo, Japan, Feb. 17, 2025 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), the Privacy-First Identity Company™, and Digital Platformer, a leader in decentralized solutions, have signed a Memorandum of Understanding (MOU) to collaborate on innovative technologies that enhance financial security, identity verification, and privacy protection, with the intention of the parties...

Continue reading

EnWave to Report First Quarter Financial Results on February 24, 2025 and Host Investor Conference Call

VANCOUVER, British Columbia, Feb. 17, 2025 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today it will report its financial results for the first quarter ended December 31, 2024 on Monday, February 24, 2025 before the market opens. The financial statements and MD&A will be available on SEDAR at www.sedarplus.ca and on the Company’s website. The Company has scheduled a conference call to discuss the results for Q1 2025 and business outlook on Monday, February 24, 2025 at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Brent Charleton, Chief Executive Officer and Dylan Murray, Chief Financial Officer will present EnWave’s results and host a question and answer period. Conference Call Details:Date: February 24, 2025Time: 7:00am PST / 10:00am ESTParticipant...

Continue reading

LGI Homes Opens Two Communities in the Oklahoma City Market

The Keystone Plan by LGI Homes at Hollow BrookThe Keystone Plan by LGI Homes at Hollow Brook features four bedrooms, two bathrooms, and a spacious family room.OKLAHOMA CITY, Feb. 17, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) announced the recent opening of two new communities in the Oklahoma City market: The Enclave at Creekside Village and Hollow Brook. Both communities offer prospective homeowners high-quality, newly constructed homes in prime locations, designed with family living in mind. The Enclave at Creekside Village – Yukon, OK Located in the charming town of Yukon, The Enclave at Creekside Village provides homebuyers with a selection of spacious one- and two-story floor plans ranging from 1,152 to 2,483 square feet. Homes in this community feature three to five bedrooms and come equipped with LGI...

Continue reading

HYTN and A1 Cannabis Announce Collaboration Agreements to Scale Production of Cannabis Products

VANCOUVER, British Columbia, Feb. 17, 2025 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade cannabis manufacturing, is pleased to announce that it has entered into a comprehensive collaboration (the “Collaboration”) with A1 Cannabis Inc. (“A1”), owner of Summit Cannabis Beverages (“Summit”). Through the Collaboration, the Company and A1 seek to enhance operational efficiency and expand both companies’ presence in the cannabis beverage market. The Collaboration is governed by both a manufacturing agreement and a consulting agreement with a letter of understanding tying them together (the “Agreements”) and has a three-year term. The Agreements allow A1 to transition its complete cannabis product...

Continue reading

Exodus Movement, Inc. Announces Offer to Acquire Banxa Holdings Inc. has Expired

OMAHA, Neb., Feb. 17, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”), a leading self-custodial cryptocurrency platform, today announced that its previously announced offer for the acquisition of all of the issued and outstanding common shares of Banxa Holdings Inc. (TSXV: BNXA) (“Banxa”) has expired without reaching an agreement with Banxa. Exodus will remain responsible stewards of capital with a disciplined approach to acquisitions. About Exodus Exodus is a financial technology leader empowering individuals and businesses with secure, user-friendly crypto software solutions. Since 2015, Exodus has made digital assets accessible to everyone through its multi-asset crypto wallets prioritizing design and ease of use. With self-custodial wallets, Exodus puts customers in full...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.